TORONTO, March 14, 2023 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that the Company has been made aware that Reunion…

Source

Previous articleBetterLife Closes $1,857,143 of Private Placement
Next articlePT398 – Lost Civilizations, DMT Entities, & Altered States of Consciousness and Early Religion